Biomolecules & Therapeutics  https://doi.org/10.4062/biomolther.2023.197
Engineered T Cell Receptor for Cancer Immunotherapy
So Won Lee and Hyang-Mi Lee*
College of Pharmacy, Dongduk Women’s University, Seoul 02748, Republic of Korea
*E-mail: hmlee@dongduk.ac.kr
Tel: +82-2-940-4159, Fax: +82-2-940-4524
Received: November 3, 2023; Revised: January 22, 2024; Accepted: January 29, 2024; Published online: June 7, 2024.
© The Korean Society of Applied Pharmacology. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Among therapeutic strategies in cancer immunotherapy, involving immune-modulating antibodies, cancer vaccine or adoptive T cell transfer, T cells has been attractive target due to their cytotoxicity toward tumor cells and tumor antigen-specific binding of receptors. Taking advantage of exclusive properties of T cells, chimeric antigen receptor (CAR)-T and T cell receptor (TCR)-T cells were generated by genetic edition of their receptors, which led an improvement in specificity and effectiveness of the T cell therapy. Adoptive cell transfer of CAR-T cells has been successful for the treatment of hematological malignancies. To expand T cell therapy to solid tumors, T cells are modified to express defined TCR targeting tumor associated antigen (TAA), which is called TCR-T therapy. Here in, this review discusses anti-tumor T cell therapies with focus on engineered TCR-T cell therapy. We describe features of TCR-T cell therapy, and clinical application of TCR-T cell therapy to non-hematological malignancies.
Keywords: Cancer immunotherapy, CAR-T cell, TCR-T cell, Solid tumor


This Article


Cited By Articles
  • CrossRef (0)

e-submission

Archives